Ardelyx reported third‑quarter product revenue of $105.5 million, a 15% year‑over‑year increase. IBSRELA generated $78.2 million, up 92% from the same period in 2024, while XPHOZAH posted $27.4 million, a 9% quarter‑over‑quarter rise.
The company raised its full‑year IBSRELA revenue guidance to $270–$275 million, up from the previous $250–$260 million range. It also announced the initiation of RDX10531, a next‑generation NHE3 inhibitor, as part of its pipeline expansion.
CEO Mike Raab said IBSRELA continues to outperform due to sustained demand and effective commercial execution, and that XPHOZAH growth remains robust despite reimbursement challenges. The company highlighted disciplined capital allocation and a strong cash position that support ongoing investment in innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.